- Aug 16, 2018
- 68
- Tinnitus Since
- Late Autumn 2016
- Cause of Tinnitus
- Unsure between azithromycin or viral infection
http://otomagnetics.net/
"Otomagnetics, a University of Maryland College Park spin-out, is developing a non-invasive method to deliver drugs and other therapeutic payloads to inner and middle ear compartments, to the eye, and into the skin.
The inner ear is behind the blood-labyrinth barrier – vessels that supply blood to the inner ear have walls that are impermeable to most drug molecules, and thus it is a challenge to deliver therapy to treat inner ear diseases. Otomagnetics' proprietary magnetic injection system has demonstrated drug delivery to the inner ear in animal models.
Otomagnetics' technology has further shown drug delivery to the middle ear in animal models without the need to puncture the eardrum. Magnetic delivery to the middle ear may provide a non-invasive treatment use. In the future, the Otomagnetic's technology may be investigated for delivering therapy into the eye, without needles."
How the technology works:
There is potential to use this as a mode of delivery for the upcoming Frequency Therapeutics treatment drug for hearing loss called FX-322: http://www.frequencytx.com/news-events/news-events-press-release-10-4-2018.php
Perhaps after more testing we will find out how much hearing loss has an effect on tinnitus and what further research needs to be expanded upon.
Inteview with co-founder of Otomagnetics:
"Otomagnetics, a University of Maryland College Park spin-out, is developing a non-invasive method to deliver drugs and other therapeutic payloads to inner and middle ear compartments, to the eye, and into the skin.
The inner ear is behind the blood-labyrinth barrier – vessels that supply blood to the inner ear have walls that are impermeable to most drug molecules, and thus it is a challenge to deliver therapy to treat inner ear diseases. Otomagnetics' proprietary magnetic injection system has demonstrated drug delivery to the inner ear in animal models.
Otomagnetics' technology has further shown drug delivery to the middle ear in animal models without the need to puncture the eardrum. Magnetic delivery to the middle ear may provide a non-invasive treatment use. In the future, the Otomagnetic's technology may be investigated for delivering therapy into the eye, without needles."
How the technology works:
There is potential to use this as a mode of delivery for the upcoming Frequency Therapeutics treatment drug for hearing loss called FX-322: http://www.frequencytx.com/news-events/news-events-press-release-10-4-2018.php
Perhaps after more testing we will find out how much hearing loss has an effect on tinnitus and what further research needs to be expanded upon.
Inteview with co-founder of Otomagnetics: